A Phase 3 interventional study of Eflornithine and Lomustine in Anaplastic Astrocytoma and Recurrent Anaplastic Astrocytoma, sponsored by Orbus Therapeutics, Inc.. Status unknown at 79 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-01-21.
Sponsored by Orbus Therapeutics, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 553 studies in Astrocytoma with a site in United States — 52 open to participants now, 81 under way, 7 of them phase 3. Astrocytoma · United States.
Among the 553 studies in Astrocytoma with a site in United States, this one is the 8th largest by enrollment of the 457 interventional ones that give a count, is one of 16 that started in 2016, is one of 26 in phase 3, and was the 435th registered.
688 studies on the registry are indexed under Astrocytoma; 80 are open to participants now.
Browse Astrocytoma studies →52 of the 553 studies in Astrocytoma with a site in United States are open now. Recruiting first, the newest first:
Inova Health Care Services · Sites in United States
Ages 18–98
Radiomedix, Inc. · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+
Institut de Recherches Internationales Servier (I.R.I.S.) · Sites in United States, Australia, Canada
Ages 12–17
The Cooper Health System · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 68 Astrocytoma studies recruiting now, 40 (59%) set no upper age limit and 14 (21%) stop at 75 or younger; 15 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
553 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 305 · Phase 2 221 · Phase 3 28 · Phase 4 2
First in 1989; this study’s year is marked. 16 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 343 is above the median of 31 across 531 interventional studies indexed under Astrocytoma.
Median enrollment 30 across the 457 interventional studies, 105 across the 40 observational. Of the 435 that completed or were terminated, 132 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
73 of 553 have an industry lead sponsor. The 10 most frequent:
Orbus Therapeutics, Inc. is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Orbus Therapeutics, Inc. has 2 studies filed under Astrocytoma — fewer than ten, so there is no comparison to draw.
32 of the studies in Astrocytoma with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04576117Phase 3National Cancer Institute (NCI)A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma | 2026-12-30 |
| NCT00978458Phase 3Eastern Cooperative Oncology GroupRadiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma | 2026-12-31 |
| NCT06108206Columbia UniversityAdaptive Radiotherapy and MRIs Based on Patients With Newly Diagnosed High-Grade Glioma | 2026-12 |
| NCT03596086David Baskin MDHSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM | 2026-12-30 |
| NCT05683808University of Vermont Medical CenterVenous Thromboembolism Prevention in Outpatients With Glioma | 2026-12-30 |
Add all 32 to your calendar (.ics) → With an account.
Among the 553 studies in Astrocytoma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the efficacy and safety of eflornithine in combination with lomustine, compared to lomustine taken alone, in treating patients whose anaplastic astrocytoma has recurred/progressed after radiation and temozolomide chemotherapy.
This study will consist of 4 study periods of up to 50 months in total, consisting of:
Screening Period - A maximum screening duration of 4 weeks.
Treatment Period - Treatment Arm A up to 24 months; Treatment Arm B up to 12 months.
End of Treatment Visit - A minimum of 4 weeks post last treatment for both arms.
Follow-Up Period - Up to approximately 36 months, or until patient death.
A total of approximately 340 patients will be randomized in a 1:1 ratio to receive either eflornithine + lomustine or lomustine alone.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients must meet all of the following inclusion criteria to be eligible for participation in this study:
First AA tumor progression or recurrence ≤ 6 months prior to randomization based on MRI using T2 hyperintesity, gadolinium (Gd)-contrast enhancement, or both. To avoid enrollment of patients with glioblastoma, patients with Gd-contrast enhancing tumors will be eligible if there is no necrosis seen on MRI and any of the following criteria is true:
Exclusion Criteria:
Patients who meet any of the following exclusion criteria are not eligible for study participation:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Eflornithine dosed on a 2 weeks on, 1 week off schedule + Lomustine dosed every 6 weeks
Drug: Eflornithine · Drug: Lomustine
Lomustine dosed every 6 weeks
Drug: Lomustine
Eflornithine 2.8 g/m2 administered orally every 8 hours on a 2 week on, 1 week off schedule
Also known as: DFMO
Lomustine 90 mg/m2 administered orally once every 6 weeks
Also known as: CCNU, CeeNU, Gleostine
Lomustine 110 mg/m2 administered orally once every 6 weeks
Also known as: CCNU, CeeNU, Gleostine
Overall survival
Time frame: 4 years
Progression-free survival (PFS)
Time frame: 4 years
Objective response rate (ORR)
Time frame: 4 years
Clinical benefit response (CBR) based on magnetic resonance imaging (MRI) criteria
Time frame: 4 years
OS rate at 18 months (OS-18)
Time frame: 18 months
Relevance of OS, PFS, ORR, and CBR to commonly used molecular/genetic biomarkers obtained from most recent pre-study tumor samples
Time frame: 4 years
Pharmacokinetic Analysis - Maximum concentrations (Cmax) of eflornithine in plasma will be determined.
Time frame: 1 Month
PK - Area under the curve (AUC) of eflornithine in plasma will be determined.
Time frame: 1 Month
Plan to share: No
No publications or documents are linked to this record.
The record gives a start of Jul 2016, a primary completion of Jun 2023 and a completion of Jun 2023. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eflornithine
Orbus Therapeutics, Inc.